Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

---

 

SCHEDULE 14D-9

 

SOLICITATION/RECOMMENDATION

STATEMENT UNDER SECTION 14(d)(4) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

---

 

Ocata Therapeutics, Inc.

(Name of Subject Company)

 

---

 

Ocata Therapeutics, Inc.

(Names of Persons Filing Statement)

 

---

 

COMMON STOCK, PAR VALUE $0.001 PER SHARE

(Title of Class of Securities)

 

---

 

67457L100

(CUSIP Number of Class of Securities)

 

---

 

Paul Wotton

President and Chief Executive Officer

33 Locke Drive

Marlborough, MA 01752

(Name, Address and Telephone Number, including area code, of Agent For Service)

 

With copies to:

Mitchell Bloom, Esq.

Andrew Goodman, Esq
William Collins, Esq.

Goodwin Procter LLP

Exchange Place

53 State Street

Boston, MA 02109

[phone]

(Name, address, and telephone numbers of person authorized to receive notices and communications on behalf of
the persons filing statement)

 

---

 

x Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

 

The information set forth under Items 1.01, 5.03, 7.01 and 9.01 of the Current Report on Form 8-K filed by Ocata Therapeutics, Inc. on November 10, 2015 (including all exhibits attached thereto) is incorporated herein by reference.

 

 

 

---